Browsing through the pipelines of recent biotech IPOs is great way to catch up on emerging targets, novel drug modalities, and science at the edge of development. Unlike conferences and publications which tend to be a lagging indicator of what’s going on in industry (with many publications only being released Read more…
June’s edition of Small Molecules of the Month features a natural product-derived RNA splicing modulator, a mTORC1-selective “bi-steric” inhibitor, numerous low-dose clinical candidates and several unusual chemical motfs (e.g. pyridine N-oxide, sulfinylamine, boronic acid). Links to articles, PDF download, and full summaries below. The H3 Biomedicine RNA splicing modulator, H3B-8800, Read more…
By Christian Gampe While biologic drugs currently dominate in immunology by sales, small molecule immunomodulators (SMIMs) are making a comeback fueled by better understanding of intracellular signaling pathways and new hit finding technologies. SMIMs can be grouped into two categories: those that engage large molecule (LM) targets in a new Read more…
Which drug hunters are making the greatest scientific contributions to drug discovery R&D? We have some drug hunters in mind…
In May’s edition of Small Molecules of the Month, we have several fascinating molecules including a mutant PI3Kα degrader in Ph. III (GDC-0077, inavolisib), a wild-type CFTR potentiator for COPD, and a Ph. III chemotherapeutic derived from an aerospace compound. Links to articles, PDF download, and full summaries below. The Read more…
On Jun. 23rd at 11AM PST, Dewakar Sangaraju and Dennis Hu will be giving a PBSS/CLSA webinar titled “Highlights from 2020’s FDA New Drug Approvals,” organized by Cyrus Khojasteh and Shichang Miao. One interesting fact about each approved small molecule drug will be shared, along with statistics and specific case Read more…